MDCT appearance of gastrointestinal stromal tumors after therapy with imatinib mesylate.
OBJECTIVE
Our objective was to determine the MDCT appearance of gastrointestinal stromal tumors (GISTs) after treatment with imatinib mesylate.


CONCLUSIONS
Cystic changes within primary and metastatic GISTs seen on MDCT in patients after imatinib mesylate therapy are evidence of disease response. Calcification may also occur in lesions that respond to therapy.
Warakaulle
Dinuke R
DR
Department of Radiology, The Churchill Hospital, Old Road, Oxford, OX3 7LJ, United Kingdom. dinuke2@hotmail.com
Gleeson
Fergus
F
D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides; D003287:Contrast Media; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D006801:Humans; D007091:Image Processing, Computer-Assisted; D000068877:Imatinib Mesylate; D007479:Iopamidol; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D001549:Benzamides; D003287:Contrast Media; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D007479:Iopamidol